Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...
The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed to boost efficacy, limit toxicity and elevate patient outcomes. Conventional oral ...
Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society ...
NexPoint Residential Trust (NXRT) is facing continued challenges on the earnings front, with losses that have deepened at an ...
A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to ...
Johnson & Johnson today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVYtm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback